Enhanced α-synuclein expression in human neurodegenerative diseases: Pathogenetic and therapeutic implications

Current Protein and Peptide Science

Volumn 10, Issue 5, 2009, Pages 476-482

  McCormack, Alison L ^a   Di Monte, Donato A ^a  

^a PARKINSON S INSTITUTE   (United States)

Author keywords

synuclein; Aggregation; Aging; Autophagy; Neurotoxins; Parkinson's disease; RNA interference; Substantia nigra

Indexed keywords

ALPHA SYNUCLEIN;

AGING; AUTOPHAGY; DEGENERATIVE DISEASE; DISEASE PREDISPOSITION; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE ENVIRONMENT INTERACTION; HUMAN; NERVE CELL PLASTICITY; NERVE INJURY; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PROTEIN AGGREGATION; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; RNA INTERFERENCE; SIGNAL TRANSDUCTION;

AGING; ALPHA-SYNUCLEIN; ANIMALS; AUTOPHAGY; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MODELS, BIOLOGICAL; NEURODEGENERATIVE DISEASES; NEURONS; POLYMORPHISM, GENETIC; PROMOTER REGIONS, GENETIC; RISK FACTORS; RNA INTERFERENCE;

EID: 70349481750     PISSN: 13892037     EISSN: None     Source Type: Journal    
DOI: 10.2174/138920309789351912     Document Type: Review

References (73)

1. Polymeropoulos, M.H.; Lavedan, C.; Leroy, E.; Ide, S.E.; Dehejia, A.; Dutra, A.; Pike, B.; Root, H.; Rubenstein, J.; Boyer, R.; Stenroos, E.S.; Chandrasekharappa, S.; Athanassiadou, A.; Papapetropoulos, T.; Johnston, W.G.; Lazzarini, A.M.; Duvoisin, R.C.; Di Iorio, G.; Golbi, L.I.; Nussbaum, R.L. Mutation in the α-synuclein gene identified in families with Parkinson's disease. Science, 1997, 276, 2045-2047.
2. Spillantini, M.G.; Crowther, R.A.; Jakes, R.; Hasegawa, M.; Goerdert, M. α-Synuclein in filamentous inclusions of Lewy bodies from Parkinson's disease and dementia with Lewy bodies. Proc. Natl. Acad. Sci. USA, 1998, 95, 6469-6473.
3. Braak, H.; Del Tredici K.; Rüb, U.; de Vos, R.A.I.; Jansen Steur, E.N.H.; Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging, 2003, 24, 197-211.
4. Baba, M.; Nakajo, S.; Tu, P.H.; Tomita, T.; Nakaya, K.; Lee, V.M.; Trojanowski, J.Q.; Iwatsubo, T. Aggregation of α-synuclein in Lewy bodies of sporadic Parkinson's disease and dementia with Lewy bodies. Am. J. Pathol., 1998, 152, 879-884.
5. Tu, P.H.; Galvin, J.E.; Baba, M.; Giasson, B.; Tomita, T.; Leight, S.; Nakajo, S.; Iwatsubo, T.; Trojanowski, J.Q.; Lee, V.M. Glial cytoplasmic inclusions in white matter oligodendrocytes of multiple system atrophy brains contain insoluble α-synuclein. Ann. Neurol., 1998, 44, 415-422.
6. Duda, J.E.; Lee, V.M.; Trojanowski, J.Q. Neuropathology of synuclein aggregates. J. Neurosci. Res., 2000, 61, 121-127.
7. Lo Bianco, C.; Ridet, J-L.; Schneider, B.L.; Déglon, N.; Aebischer, P. α-Synucleinopathy and selective dopaminergic loss in a rat lentiviral-based model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2002, 99, 10813-10818.
8. Kirik, D.; Annett, L.E., Burger, C.; Muzyczka, N.; Mandel, R.J.; Björklund, A. Nigrostriatal α-synucleinopathy induced by viral vector-mediated overexpression of human α-synuclein: a new primate model of Parkinson's disease. Proc. Natl. Acad. Sci. USA, 2003, 100, 2884-2889.
9. Eslamboli, A.; Romero-Ramos, M.; Burger, C.; Bjorklund, T.; Muzyczka, N.; Mandel, R.J.; Baker, H.; Ridley, RM.; Kirik, D. Long-term consequences of human α-synuclein overexpression in the primate ventral midbrain. Brain, 2007, 130, 799-815.
10. Singleton, A.B.; Farrer, M.; Johnson, J.; Singleton, A.; Hague S.; Kachergus, J.; Hulihan, M.; Peuralinna, T.; Dutra, A.; Nussbaum, R.; Lincoln, S.; Crawley, A.; Hanson, M.; Maraganore, D.; Adler, C.; Cookson, M.R.; Muenter M.; Baptista, M.; Miller, D.; Blancato, J.; Hardy, J.; Gwinn-Hardy, K. α-Synuclein locus triplication causes Parkinson's disease. Science, 2003, 302, 841.
11. Farrer, M.; Kachergus, J.; Forno, L.; Lincoln, S.; Wang, D.S.; Hulihan, M.; Maraganore, D.; Gwinn-Hardy, K.; Wszolek, Z.; Dickson, D.; Langston J.W. Comparison of kindreds with parkinsonism and α-synuclein genomic multiplications. Ann. Neurol., 2004, 55, 174-179.
12. Rockenstein, E.; Hansen, L.A.; Mallory, M.; Trojanowski, J.Q.; Galasko, D.; Masliah, E. Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease. Brain Res., 2001, 914, 48-56.
13. Chiba-Falek, O.; Lopez, G.J.; Nussbaum, R.L. Levels of α-synuclein mRNA in sporadic Parkinson's disease patients. Mov. Disord., 2006, 21, 1703-1708.
14. Neystat, M.; Lynch, T.; Przedborski, S.; Kholodilov, N.; Rzhetskaya, M.; Burke, R.E. Alpha-synuclein expression in the substantia nigra and cortex in Parkinson's disease. Mov. Disord., 1999, 14, 417-422.
15. Kingsbury, A.E.; Daniel, S.E.; Sangha, H.; Eisen, S.; Lees, A.J.; Foster, O.J. Alteration in α-Synuclein mRNA expression in Parkinson's disease. Mov. Disord., 2004, 19, 162-170.
16. Tan, E.K.; Chandran, V.R.; Fook-Chong, S.; Shen, H.; Yew, K.; Teoh, M.L.; Yuen, Y.; Zhao, Y. α-Synuclein mRNA expression in sporadic Parkinson's disease. Mov. Disord., 2005, 20, 620-623.
17. Cantuti-Castelvetri, I.; Keller-McGandy, C.; Bouzou, B.; Asteris, G.; Clark, T.W.; Frosch, M.P.; Standaert, D.G. Effects of gender on nigral gene expression and Parkinson's disease. Neurobiol. Dis., 2007, 26, 606-614.
18. Gründemann, J.; Schlaudraff, F.; Haeckel, O.; Liss, B. Elevated α-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease. Nucleic Acids Res., 2008, 36, e38.
19. Weinreb, P.H.; Zhen, W.; Poon, A.W.; Conway, K.A.; Lansbury, P.T. Jr. NACP, a protein implicated in Alzheimer's disease and learning, is natively unfolded. Biochemistry, 1996, 35, 13709-13715.
20. Eliezer, D.; Kutluay, E.; Bussell, R.; Jr.; Browne, G. Conformational properties of α-synuclein in its free and lipid-associated states. J. Mol. Biol., 2001, 307, 1061-1073.
21. Wood, S.J.; Wypych, J.; Steavenson, S.; Louis, J.C.; Citron, M.; Biere, A.L. α-Synuclein fibrillogenesis is nucleation-dependent: implications for the pathogenesis of Parkinson's disease. J. Biol. Chem., 1999, 274, 19509-19512.
22. Conway, K.A.; Harper, J.D.; Lansbury, P.T. Jr. Fibrils formed in vitro from α-synuclein and two mutant forms linked to Parkinson's disease are typical amyloid. Biochemistry, 2000, 39, 2552-2563.
23. Uversky, V.N.; Lee, H.J.; Li, J.; Fink, A.L.; Lee, S.J. Stabilization of partially folded conformation during α-synuclein oligomerization in both purified and cytosolic preparations. J. Biol. Chem., 2001, 276, 43495-43498.
24. Uversky, V.N.; Li, J.; Fink, A.L. Evidence for a partially folded intermediate in α-synuclein fibril formation. J. Biol. Chem., 2001, 276, 10737-10744.
25. Shtilerman, M.D.; Ding, T.T.; Lansbury, P.T.; Jr. Molecular crowding accelerates fibrillization of α-synuclein: could an increase in the cytoplasmic protein concentration induce Parkinson's disease? Biochemistry, 2002, 41, 3855-3860.
26. Rochet, J.C.; Outeiro, T.F.; Conway, K.A.; Ding, T.T.; Volles, M.J.; Lashuel, H.A.; Bieganski, R.M.; Lindquist, S.L.; Lansbury, P.T. Interactions among α-synuclein, dopamine, and biomembranes: some clues to understanding neurodegeneration in Parkinson's disease. J. Mol. Neurosci., 2004, 23, 23-34.
27. Vila, M.; Vukosavic, S.; Jackson-Lewis, V.; Neystat, M.; Jakowec, M.; Przedborski, S. α-Synuclein up-regulation in the substantia nigra dopaminergic neurons following administration of the parkinsonian toxin MPTP. J. Neurochem., 2004, 74, 721-729.
28. Manning-Boǧ, A.B.; McCormack, A.L.; Li, J.; Uversky, V.N.; Fink, A.L.; Di Monte, D.A. The herbicide paraquat causes upregulation and aggregation of α-synuclein in mice. J. Biol. Chem., 2002, 277, 1641-1644.
29. Fornai, F.; Lenzi, P.; Ferrucci, M.; Lazzeri, G.; di Poggio, A.B.; Natale, G.; Busceti, C.L.; Biagioni, F.; Giusiani, M.; Ruggieri, S.; Paparelli, A. Occurrence of neuronal inclusions combined with increased nigral expression of α-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice. Brain Res. Bull., 2005, 65, 405-413.
30. Kowall, N.W.; Hantraye, P.; Brouillet, E.; Beal, M.F.; McKee, A.C.; Ferrante, R.J. MPTP induces α-synuclein aggregation in the substantia nigra of baboons. Neuroreport, 2000, 11, 211-213.
31. Purisai, M.G.; McCormack, A.L.; Langston, W.J.; Johnston, L.C.; Di Monte, D.A. α-Synuclein expression in the substantia nigra of MPTP-treated non-human primates. Neurobiol. Dis., 2005, 20, 898-906.
32. Clayton, D.F.; George, J.M. The synucleins: a family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci., 1998, 21, 249-254.
33. Fortin, D.L.; Nemani, V.M.; Voglmaier, S.M.; Anthony, M.D.; Ryan, T.A.; Edwards, R.H. Neural activity controls the synaptic accumulation of α-synuclein. J. Neurosci., 2005, 25, 10913-10921.
34. McCormack, A.L.; Mak, S.K.; Shenasa, M.; Langston, J.W.; Forno, L.S.; Di Monte, D.A. Pathological modifications of α-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. J. Neuropathol. Exp. Neurol., 2008, 67, 793-802.
35. Giasson, B.I.; Duda, J.E.; Murray, I.V.; Chen, Q.; Souza, J.M.; Hurtig, H.I.; Ischiropoulos, H.; Trojanowski, J.Q.; Lee, V.M. Oxidative damage linked to neurodegeneration by selective α-synuclein nitration in synucleinopathy lesions. Science, 2000, 290, 985-989.
36. Fujiwara, H.; Hasegawa, M.; Dohmae, N.; Kawashima, A.; Masliah, E.; Goldberg, M.S.; Shen, J.; Takio, K.; Iwatsubo, T. α-Synuclein is phosphorylated in synucleinopathy lesions. Nat. Cell Biol., 2002, 4, 160-164.
37. Uversky V.N.; Li, J.; Fink, A.L. Pesticides directly accelerate the rate of α-synuclein fibril formation: a possible risk factor in Parkinson's disease. FEBS Lett., 2001, 500, 105-108.
38. Di Monte, D.A. The environment and Parkinson's disease: is the nigrostriatal system preferentially targeted by neurotoxins? Lancet, 2003, 2, 531-538.
39. Burns, R.S.; Chiueh, C.C.; Markey, S.P.; Ebert, M.H.; Jacobowitz, D.M.; Kopin, I.J. A primate model of parkinsonism: selective destruction of the dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc. Natl. Acad. Sci. USA, 1983, 80, 4546-4550.
40. Di Monte, D.A.; McCormack, A.L.; Petzinger, G.M.; Janson, A.M.; Quik, M.; Langston, J.W. Relationship between nigrostriatal denervation, parkinsonism and dyskinesias in the MPTP primate model. Mov. Disord., 2000, 15, 459-466.
41. Ascherio, A.; Chen, H.; Weisskopf, M.G.; O'Reilly, E.; McCullough, M.L.; Callee, E.E; Schwarzschild, M.A.; Thun, M.J. Pesticide exposure and risk for Parkinson's disease. Ann. Neurol., 2006, 60, 197-203.
42. Kamel, F.; Tanner, C.; Umbach, D.; Hoppin, J.; Alavanja, M.; Blair, A.; Comyns, K.; Goldman, S.; Korell, M.; Langston, J.; Ross, G.; Sandler, D. Pesticide exposure and self-reported Parkinson's disease in the agricultural health study. Am. J. Epidemiol., 2007, 15, 364-374.
43. Van Den Eeden, S.K.; Tanner, C.M.; Bernstein, A.L.; Fross, R.D.; Leimpeter, A.; Bloch. D.A.; Nelson, L.M. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am. J. Epidemiol., 2003, 157, 1015-1022.
44. Kish, S.J.; Shannak, K.; Rajput, A.; Deck, J.H.; Hornykiewicz, O. Aging produces a specific pattern of striatal dopamine loss: implications for the etiology of Parkinson's disease. J. Neurochem., 1992, 58, 642-648.
45. Emborg, M.E.; Ma, S.Y.; Mufson, E.J.; Levey, A.I.; Taylor, M.D.; Brown, W.D.; Holden, J.E.; Kordower, J.H. Age-related declines in nigral neuron function correlate with motor impairments in rhesus monkeys. J. Comp. Neurol., 1998, 401, 253-265.
46. Gerhardt, G.A.; Cass, W.A.; Yi, A.; Zhang, Z.; Gash, D.M. Changes in somatodendritic but not terminal dopamine regulation in aged rhesus monkeys. J. Neurochem., 2002, 80, 168-177.
47. McCormack, A.L.; Di Monte, D.A.; Delfani, K.; Irwin, I.; DeLanney, L.E.; Langston, W.J.; Janson, A.M. Aging of the nigrostriatal system in the squirrel monkey. J. Comp. Neurol., 2004, 471, 387-395.
48. Collier, T.J.; Lipton, J.; Daley, B.F.; Palfi, S.; Chu, Y.; Sortwell, C.; Bakay, R.A.; Sladek, J.R. Jr.; Kordower, J.H. Age-related changes in the nigrostriatal dopamine system and the response to MPTP in non-human primates: diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiol. Dis., 2007, 26, 56-65.
49. Cruz-Sanchez, F.F.; Cardozo, A.; Tolosa, E. Neuronal changes in the substantia nigra with aging: a golgi study. J. Neuropathol. Exp. Neurol., 1995, 54, 74-81.
50. Zecca, L.; Fariello, R.; Riederer, P.; Sulzer, D.; Gatti, A.; Tampellini, D. The absolute concentration of nigral neuromelanin, assayed by a new sensitive method, increases throughout life and is dramatically decreased in Parkinson's disease. FEBS Lett., 2002, 510, 216-220.
51. Li, W.; Lesuisse, C.; Xu, Y.; Troncoso, J.C.; Price, D.L.; Lee, M.K. Stabilization of α-synuclein protein with aging and familial Parkinson's disease-linked A53T mutation. J. Neurosci., 2004, 24, 7400-7409.
52. Chu, Y.; Kordower, J.H. Age-associated increases of α-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease? Neurobiol. Dis., 2007, 25, 134-149.
53. Petersen, K.; Olesen, O.F.; Mikkelsen, J.D. Developmental expression of α-synuclein in rat hippocampus and cerebral cortex. Neuroscience, 1999, 91, 651-659.
54. Adamczyk, A.; Solecka, J.; Strosznajder, J.B. Expression of α-synuclein in different brain parts of adult and aged rats. J. Physiol. Pharmacol., 2005, 56, 29-37.
55. Vernace, V.A.; Schmidt-Glenewinkel, T.; Figueiredo-Pereira, M.E. Aging and regulated protein degradation: who has the UPPer hand? Aging Cell., 2007, 6, 599-606.
56. Massey, A.; Kiffin, R.; Cuervo, A.M. Pathophysiology of chaperone-mediated autophagy. Int. J. Biochem. Cell Biol., 2004, 36, 2420-2434.
57. Parkkinen, L.; Soininen, H.; Alafuzoff, I. Regional distribution of α-synuclein pathology in unimpaired aging and Alzheimer's disease. J. Neuropathol. Exp. Neurol., 2003, 62, 363-367.
58. Jellinger, K. Lewy body-related α-synucleinopathy in the aged human brain. J. Neural Transm., 2004, 111, 1219-1235.
59. Mikolaenko, I.; Pletnikova, O.; Kazwas, C.H.; O'Brien, R.; Resnick, S.M.; Crain, B.; Troncoso, J.C. Alpha-synuclein lesions in normal aging, Parkinson's disease, and Alzheimer's disease: Evidence from the Baltimore longitudinal study of aging (BLSA). J. Neuropathol. Exp. Neurol., 2005, 64, 156-162.
60. Dickson, D.W.; Fujishiro, H.; DelleDonne, A.; Menke, J.; Ahmed, Z.; Klos, K.J.; Josephs, K.A.; Frigerio, R.; Burnett, M.; Parisi, J.E.; Ahlskog, J.E. Evidence that incidental Lewy body disease is presymptomatic Parkinson's disease. Acta Neuropathol., 2008, 115, 437-444.
61. Pals, P.; Lincoln, S.; Manning, J.; Heckman, M.; Skipper, L.; Hulihan, M., Van den Broeck, M.; De Pooter, T.; Cras, P.; Crook, J.; Van Broeckhoven, C.; Farrer, M. α-Synuclein promoter confers susceptibility to Parkinson's disease. Ann. Neurol., 2004, 56, 591-595.
62. Fuchs, J.; Tichopad, A.; Golub, Y.; Munz, M.; Schweitzer, K.J.; Wolf, B.; Berg, D.; Mueller, J.C.; Gasser, T. Genetic variability on the SNCA gene influences α-synuclein in the blood and brain. FASEB J., 2008, 22, 1327-1334.
63. Elbashir, S.M.; Harborth, J.; Lendeckel, W.; Yalcin, A.; Weber, K.; Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature, 2001, 411, 494-498.
64. Manfredsson, F.P.; Lewin, A.S.; Mandel, R.J. RNA knockdown as a potential therapeutic strategy in Parkinson's disease. Gene Ther., 2006, 13, 517-524.
65. Webb, J.L.; Ravikumar, B.; Atkins, J.; Skepper, J.N.; Rubinsztein, D.C. α-Synuclein is degraded by both autophagy and the proteasome. J. Biol. Chem., 2003, 278, 25009-25013.
66. Cuervo, A.M.; Stefanis, L.; Fredenburg, R.; Lansbury, P.T.; Sulzer, D. Impaired degradation of mutant α-synuclein by chaperone-mediated autophagy. Science, 2004, 305, 1292-1295.
67. Vogiatzi, T.; Xilouri, M.; Vekrellis, K.; Stefanis, L. Wild-type α-synuclein is degraded by chaperone-mediated autophagy and macroautophagy in neuronal cells. J. Biol. Chem., 2008, 283, 23542-23556.
68. Williams, A.; Sarkar, S.; Cuddon, P.; Ttofi, E.K.; Saiki, S.; Siddiqi, F.H.; Jahreiss, L.; Fleming, A.; Goldsmith, P.; O'Kane, C.J.; Floto, R.A.; Rubinsztein, D.C. Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Nat. Chem. Biol., 2008, 4, 295-305.
69. Martinez-Vicente, M.; Cuervo, A.M. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol., 2007, 6, 352-361.
70. Li, J.; Zhu, M.; Manning-Bog, A.B.; Di Monte, D.A.; Fink, A.L. Dopamine and L-Dopa disaggregate amyloid fibrils: implications for Parkinson's and Alzheimer's disease. FASEB J., 2004, 18, 962-964.
71. Zhu, M.; Rajamani, S.; Kaylor, J.; Han, S.; Zhou, F.; Fink, A.L. The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils. J. Biol. Chem., 2004, 279, 26846-26857.
72. Norris, E.H.; Giasson, B.I.; Hodara, R.; Xu, S.; Trojanowski, J.Q.; Ischiropoulos, H.; Lee, V.M. Reversible inhibition of α-synuclein fibrillization by dopaminochrome-mediated conformational alterations. J. Biol. Chem., 2005, 280, 21212-21219.
73. Beyer, K.; Ariza, A. The therapeutic potential of α-synuclein antiaggregatory agents for dementia with Lewy bodies. Curr. Med. Chem., 2008, 15, 2748-2759.